BDRX_OUT_1 [2025-04-02 13:47:28 -0400] 2955 Bytes | 831 tokens | Cum: 831 tkns (10.39% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:47:27 PM on Wed Apr 02, 2025 -0400, and I'm charging into Biodexa Pharmaceuticals (BDRX), popping from 1.2 to 1.415. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Biodexa Pharmaceuticals (BDRX)
IPO: 2015-12-07 (9 Years Ago)
Market Cap: $802,310
Shares Outstanding: 6,685,920,000
Exchange: XNAS
Description: Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Here's the first list of news for Biodexa Pharmaceuticals:

C1 - Mar-19-25 07:00AM - With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
C2 - Mar-10-25 08:30AM - Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
C3 - Mar-06-25 08:30AM - Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
C4 - Feb-24-25 08:30AM - Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use
C5 - Feb-19-25 06:00AM - Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
C6 - Feb-13-25 08:30AM - Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
C7 - Feb-12-25 07:30AM - Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
C8 - Feb-10-25 08:30AM - Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Prior AI Reports for BDRX:
1. 2025-03-19 – Score: 30 – Target: 2.6000 – Highs: 2.6500 / 2.2000 / 1.94
significant-sales-drop-questions-long-term-viability

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Biodexa Pharmaceuticals (BDRX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

BDRX_OUT_3 [2025-04-02 13:47:33 -0400] 1099 Bytes | 272 tokens | Cum: 1105 tkns (13.81% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter**
Date: Mar-19-25 07:00AM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=1001827

The first and only All-in-one subscription platform offering
all of your PR Distribution and Media Outreach Tools in one
single solution.Monthly & Annual Subscriptions.

Find & create journalist lists with the most up to date database in the industry.

Personalize and customize your pitch for maximum engagement.

Discover your brand, industry, and competitor mentions.

The first and only All-in-one subscription platform that offers you the ability
to manage all of your IR communications needs from a single
source.Explore our IR subscriptions

Ensure your IR Site is accessible for your entire audie

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_5 [2025-04-02 13:47:33 -0400] 813 Bytes | 243 tokens | Cum: 1418 tkns (17.72% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T20:00:54Z - Best Nanotechnology Stocks To Research - March 31st...
A2 - 2025-03-31T20:04:21Z - Promising Nanotechnology Stocks To Keep An Eye On - March 30th...
A3 - 2025-03-30T20:02:51Z - Promising Nanotechnology Stocks To Research - March 29th...
A4 - 2025-03-29T20:01:57Z - Nanotechnology Stocks To Keep An Eye On - March 28th...
A5 - 2025-03-28T20:04:51Z - Top Nanotechnology Stocks Worth Watching - March 27th...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

BDRX_OUT_7 [2025-04-02 13:47:34 -0400] 1098 Bytes | 271 tokens | Cum: 1691 tkns (21.14% of 8k)
==========================================================================

Showing A1 (chunk 1 of 9): A1:
**Best Nanotechnology Stocks To Research - March 31st**Date: 2025-04-01Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/best-nanotechnology-stocks-to-research-march-31st-2025-03-31/OSI Systems, NVE, Biodexa Pharmaceuticals, Virpax Pharmaceuticals, Clene, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks refer to shares in companies that develop and commercialize technologies at the nanoscale, often involving the manipulation of matter at the atomic or molecular level. These companies typically operate in fields such as electronics, healthcare, and advanced materials, offering potential growth from innovative breakthroughs while also carrying risks related to emerging technologies and market volatility. These companies had the high

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_9 [2025-04-02 13:47:35 -0400] 1203 Bytes | 366 tokens | Cum: 2059 tkns (25.74% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-29T20:00:00Z - BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
B2 - 2024-10-23T20:00:00Z - BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
B3 - 2024-07-12T09:35:41Z - Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
B4 - 2024-07-11T18:02:49Z - Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga
B5 - 2024-07-02T12:30:00Z - Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
B6 - 2024-06-24T12:30:00Z - Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDRX_OUT_11 [2025-04-02 13:47:38 -0400] 667 Bytes | 185 tokens | Cum: 2246 tkns (28.07% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39745122/why-ericsson-shares-are-trading-higher-here-are-20-stocks-moving-premarketEricsson reported better-than-expected Q2 sales and issued guidance, causing its shares to rise in pre-market trading. Several other stocks also saw significant pre-market movement, both positive and negative.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

BDRX_OUT_13 [2025-04-02 13:47:39 -0400] 238 Bytes | 59 tokens | Cum: 2356 tkns (29.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

BDRX_OUT_15 [2025-04-02 13:47:51 -0400] 3284 Bytes | 833 tokens | Cum: 3192 tkns (39.90% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+-------------------------+
| Volume: 182,176 | Perf Month: -51.78% | Option/Short: No / Yes | Sales Y/Y TTM: -83.72% |
+-------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 1.55M | Perf Quarter: -66.66% | Short Float: - | ROE: -96.61% |
+-------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.18 | Index: - | Short Ratio: 0.04 | ROI: -75.99% |
+-------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 30.35 | Market Cap: 0.78M | Short Interest: 0.06M | Sales Surprise: 538.55% |
+-------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.34 | Shs Outstand: 0.36M | Beta: 1.20 | EPS Surprise: -49.55% |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA20: -30.00% | Shs Float: - | Sales Q/Q: -100.00% | P/E: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA50: -57.95% | Inst Own: 1.27% | Sales past 5Y: - | Earnings: - |
+-------------------+-----------------------+------------------------+-------------------------+
| SMA200: -84.67% | Insider Own: - | Employees: - | |
+-------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -9.38% | Insider Trans: - | Debt/Eq: 0.04 | |
+-------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.66
Average Volume: 3005403.26
30-Day High: 3.11
30-Day Low: 1.2
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

BDRX_OUT_17 [2025-04-02 13:47:55 -0400] 676 Bytes | 167 tokens | Cum: 3596 tkns (44.95% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

BDRX_IN_19 [2025-04-02 13:47:55 -0400] 126 Bytes | 29 tokens | Cum: 3711 tkns (46.39% of 8k)
==========================================================================

====================================
[2025-04-02 13:47:55] # Analysis Completed
Elapsed Time: 28.25 seconds